Insider Selling: Phreesia (NYSE:PHR) Insider Sells 10,063 Shares of Stock

Phreesia, Inc. (NYSE:PHR) insider Yvonne Hui sold 10,063 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $9.08, for a total transaction of $91,372.04. Following the completion of the sale, the insider directly owned 25,991 shares in the company, valued at $235,998.28. This represents a 27.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Phreesia Stock Up 0.1%

Shares of PHR traded up $0.01 during midday trading on Friday, hitting $9.18. The stock had a trading volume of 1,598,518 shares, compared to its average volume of 1,974,571. The firm has a market cap of $557.50 million, a price-to-earnings ratio of 305.83 and a beta of 0.86. The company has a 50 day simple moving average of $11.00 and a two-hundred day simple moving average of $16.40. Phreesia, Inc. has a twelve month low of $7.77 and a twelve month high of $32.76. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.53.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). The firm had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. Phreesia had a return on equity of 3.23% and a net margin of 0.48%.The firm’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.11) earnings per share. On average, analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. bought a new stake in shares of Phreesia during the third quarter worth approximately $32,000. Van ECK Associates Corp increased its stake in shares of Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares during the period. Asset Management One Co. Ltd. acquired a new stake in Phreesia during the 3rd quarter worth approximately $45,000. Rockefeller Capital Management L.P. boosted its stake in Phreesia by 354.6% in the 4th quarter. Rockefeller Capital Management L.P. now owns 2,755 shares of the company’s stock valued at $47,000 after purchasing an additional 2,149 shares during the period. Finally, KBC Group NV boosted its stake in Phreesia by 83.4% in the 4th quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after purchasing an additional 1,568 shares during the period. 92.10% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the stock. Wells Fargo & Company cut their price objective on shares of Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Citizens Jmp restated a “market perform” rating on shares of Phreesia in a research note on Wednesday, April 1st. Citigroup reaffirmed a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada started coverage on Phreesia in a report on Friday, January 9th. They set a “moderate buy” rating and a $26.00 target price on the stock. Twelve analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.82.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.